To Study AER Platform Technology and Biobetters
ST Pharm, a subsidiary of Dong-A Socio Group, announced on Feb. 23 that it signed an agreement with Multiverse Pharma in the United States for joint research on new antibody-encoding (AER) platform technology and biobetter mRNA drugs.
Under the agreement, ST Pharm and Multiverse Pharma will develop first-in-class mRNA medicines and biobetter candidates with improved selectivity, stability, and immunogenicity for antibody drugs whose mechanism of action has been identified and whose safety and efficacy were proven through clinical trials.
An AER platform technology built through this agreement will combine ST Pharm’s mRNA technology and Multibus Pharma’s protein engineering technology.
A use of Multiverse Pharma’s protein design technology resulted in the creation of bio-better antibodies through a process to optimize proteins constituting antibodies.